<DOC>
	<DOC>NCT01067365</DOC>
	<brief_summary>Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism</brief_title>
	<detailed_description>The objectives of this study were to evaluate the safety and efficacy of AndroxalÂ® administered orally once daily for one year in men with secondary hypogonadism and who had completed ZA-003.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Total serum testosterone concentrations &lt; 300 ng/dL at baseline Presence or history of prostate cancer Elevated PSA &gt; 3.5 ng/mL Additional inclusion and exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Secondary Hypogonadism</keyword>
</DOC>